518-61-6 Usage
Description
Dacemazine, also known as levomepromazine, is a phenothiazine antipsychotic medication that is primarily used to treat psychosis, schizophrenia, and severe behavioral problems in children. It works by blocking the action of dopamine and serotonin in the brain, which helps to regulate mood, behavior, and thought processes.
Used in Pharmaceutical Industry:
Dacemazine is used as an antipsychotic medication for treating psychosis, schizophrenia, and severe behavioral problems in children. It is effective in regulating mood, behavior, and thought processes by blocking the action of dopamine and serotonin in the brain.
Used in Palliative Care:
Dacemazine is used as a sedative to alleviate symptoms of agitation and distress, particularly in palliative care settings. This helps provide comfort and improve the quality of life for patients facing end-of-life situations.
Common side effects of Dacemazine include drowsiness, dizziness, and dry mouth. However, it can also cause more serious side effects such as low blood pressure, breathing difficulties, and seizures in rare cases. It is typically taken by mouth in tablet form, but can also be administered intravenously in hospital settings. Dacemazine should be used with caution in elderly patients and those with pre-existing heart conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 518-61-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,1 and 8 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 518-61:
(5*5)+(4*1)+(3*8)+(2*6)+(1*1)=66
66 % 10 = 6
So 518-61-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H16N2OS/c1-17(2)11-16(19)18-12-7-3-5-9-14(12)20-15-10-6-4-8-13(15)18/h3-10H,11H2,1-2H3
518-61-6Relevant articles and documents
Phenothiazinealkaneamines for treatment of neurotoxic injury
-
, (2008/06/13)
Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows such conditions as stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of a phenothiazinealkaneamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites. Compounds of most interest are those of the formula STR1 wherein each of R1 and R2 is hydrido; wherein each of R3 and R4 is independently selected from hydrido, methyl and ethyl; wherein each of R5 and R6 is independently selected from methyl, ethyl and n-propyl; wherein X is sulfur; wherein m is zero; and wherein n is two.